Health news and discussion on TalkFuse.
New treatment may reverse disease that plagues over a quarter of women over age 65
A small trial in Spain suggests that an infusion of patients’ own engineered stem cells may reduce fractures and improve bone density in women with advanced osteoporosis. The findings are notable because osteoporosis weakens bones and is common among older women, but the treatment remains experimental and is years from routine use.
The trial followed 10 women for two years after a single infusion. Their average fractures fell from eight a year to 0.5, a reported 94% sustained reduction; bone tissue increased by 70% after four months, while pain and disability scores also improved. The study had no control group, and some participants were taking osteoporosis medicines, so the results need testing in a larger trial that will compare cells from patients and donors with no cell treatment.
In short
- Experimental stem cell infusions sharply reduced fractures in a 10-person trial.
- Participants’ average fractures fell from eight a year to 0.5.
- Larger controlled trials are needed before the treatment can be used widely.
Explained simply
Osteoporosis is a condition that makes bones weaker and more likely to break, often after a minor fall. It becomes more common with age and affects many women after the menopause, when changes in hormone levels can speed up bone loss.
The research involved women with advanced osteoporosis and used stem cells taken from each patient, altered in a laboratory and given back through an infusion. Stem cells can develop into other types of cell, but this approach is experimental; the small study had no comparison group, so it cannot show how much the treatment itself caused the reported changes.
Larger studies are needed to assess whether the treatment is safe and effective and how it compares with existing medicines. This matters because fractures can cause lasting pain, limit movement and reduce independence, while current treatments do not work equally well for everyone.